Fig. 5: Blood pressure versus concentrations of free aflibercept in plasma. | Eye

Fig. 5: Blood pressure versus concentrations of free aflibercept in plasma.

From: Systemic exposure to aflibercept after intravitreal injection in premature neonates with retinopathy of prematurity: results from the FIREFLEYE randomized phase 3 study

Fig. 5: Blood pressure versus concentrations of free aflibercept in plasma.The alternative text for this image may have been generated using AI.

Change from baseline to day 1 in A systolic blood pressure and B diastolic blood pressure versus concentrations of free aflibercept in plasma at day 1 for individual infants. BP blood pressure, LLOQ lower limit of quantitation, TESAE treatment-emergent serious adverse event. Infants with TESAEs during the first 30 days following the start of treatment who had missing values for either aflibercept plasma concentrations and/or BP values at single time points are not included in the figure. Values below LLOQ were substituted by 0. LLOQ was 15.6 ng/mL for free aflibercept.

Back to article page